[Insert deep, meaningful, and/or witty title here]

derek’s hands on stiles’ hips, one thumb sneaking beneath the fabric of his shirt to brush against stiles’ stomach

stiles pressing his thumb against Derek’s bottom teeth and tongue before kissing him.

derek pulling stiles chest to chest by the belt loops of his pants

stiles being a biter more than derek is: biting at derek’s lips while they’re making out or at his ears playfully while they’re waking up or at his neck while they’re hugging or at his fingers while they’re just sitting beside one another; lifting his hand and pressing his own fingers down the length of Derek’s, bringing them up to brush against his lips before pinning them gently with his teeth

it’s about derek having lost everything he’s ever loved, not once but again and again.

and again.

it’s about him resolving himself into being okay with nothing—resolving himself to the reality that he can’t have good things, doesn’t deserve good things

and then—and then, along comes Stiles Stilinski, who loves like a nuclear detonation, who loves like it’s a fight with his life on the line and he’d never been taught how to lose, and derek feels like he’s been given this priceless thing to be treasured, he can’t believe he’s deserving of it

because—derek does know how to lose. it’s all he’s been taught how to do. can feel it the first time they kiss: this phantom, muscle memory of what it would be like to lose stiles’ love

so he holds it tightly to him, cupped gently, so gently, in his palms, like a beating flame kept lit by the reverence and heat of his own heart

and stiles—stiles needs derek. his love, his touch, his voice, his heartbeat under his hand, yes, but more than that he needs derek to understand how worthy he is of love, needs it so badly it’s like a hunger beneath his teeth

For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.

That routine just changed.

On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.

This is not a minor update to an existing drug.

It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.

Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.

That means reducing from 365 injections a year down to just 52.

For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.

It represents relief.

How the Drug Actually Works

Understanding why this injection lasts a full week requires a quick look inside the body.

Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.

Awiqli works differently.

Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.

This attachment creates a slow-release reservoir.

Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...

What Comes Next

Awiqli is not standing alone in this space for long.

Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.

If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.

The broader direction of travel in diabetes care is unmistakable.

Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...

A Small Shot With Large Implications

It is easy to look at a once-weekly injection and see only a scheduling change.

But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.

Diabetes management has always asked a lot of people.

It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.

Anything that reduces that load, without reducing the quality of care, is worth taking seriously.

For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.

That is the real significance of what the FDA approved on March 26, 2026.

Not just a new drug.

A new way of keeping people healthy, one week at a time.

Meanwhile at Hawkins Community Pool

🔪🔪🔪 в вк не репостить🔪🔪🔪

first part: